Table 1 |
||||
| Characteristics of Eligible Patient Population, Study vs. Control Sites | ||||
| STUDY (n = 16,584) | CONTROL (n = 13,423) | P-Value | ||
| Mean Age (yrs) | 61 | 60 | <.0001 | |
| % Female | 49.9 | 51.8 | <.0001 | |
| Race/Ethnicity (%) | ||||
| Asian/PI | 9.0 | 12.3 | <.0001 | |
| Black | 6.1 | 16.2 | <.0001 | |
| Hispanic | 9.8 | 12.6 | <.0001 | |
| Native American | 1.3 | 1.3 | 0.97 | |
| White | 62.0 | 44.4 | <.0001 | |
| Other/Multiple | 2.9 | 2.2 | <.0001 | |
| Missing Race | 8.9 | 11.0 | <.0001 | |
| Comorbidities | ||||
| Mean Number of Comorbidities* | 1.23 | 1.25 | 0.01 | |
| Has Diabetes (%) | 77.5 | 80.4 | <.0001 | |
| Current Smoker (%) | 8.9 | 9.0 | 0.77 | |
| Mean Risk Factor Values at Baseline** | ||||
| Systolic Blood Pressure (mm Hg) | 131 | 132 | 0.18 | |
| LDL-cholesterol (mg/dL) | 100 | 98 | <0.001 | |
| Hemoglobin A1c (%) | 7.3 | 7.3 | 0.13 | |
| Mean # Medication Classes, Baseline | ||||
| Blood Pressure Medications | 1.74 | 1.82 | <.0001 | |
| Diabetes Medications | 1.22 | 1.23 | 0.19 | |
| Dyslipidemia Medications | 0.70 | 0.70 | 0.35 | |
| On Max Med Therapy at Baseline (%) | ||||
| Simvastatin/Atorvastatin 80 mg | 12.3 | 13.8 | <.0001 | |
| 3 or more Blood Pressure Meds | 27.8 | 31.0 | <.0001 | |
| Insulin, if has diabetes | 20.0 | 20.5 | 0.38 | |
| Baseline control rates (%) Entire PHASE Populations - by priority level | ||||
| Priority 1: SBP <140 mmHg | 83.5 | 81.8 | ||
| Priority 4: SBP <130 mmHg | 61.1 | 60.7 | ||
| Priority 2: LDL-c <130 mg/dL | 90.2 | 90.2 | ||
| Priority 5: LDL-c <100 mg/dL | 71.8 | 71.7 | ||
| Priority 3: A1c <9% | 90.3 | 90.9 | ||
| Priority 6: A1c <7% | 60.5 | 60.0 | ||
*Comorbidity count based on whether patient is flagged in the Population Management Tool as being in these populations: abdominal aortic aneurism, coronary artery disease, chronic kidney disease, diabetes, peripheral artery disease, and cerebrovascular disease.
Selby et al. BMC Health Services Research 2012 12:183 doi:10.1186/1472-6963-12-183
